Related Experiment Video
Updated: Feb 4, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Deep and Durable Response With Combination CTLA-4 and PD-1 Blockade in Mismatch Repair (MMR)-proficient Endometrial
Michael S Oh1, Young Kwang Chae1,2
1Northwestern University Feinberg School of Medicine.
Abstract:
Immune checkpoint inhibitors have shown promising efficacy in multiple cancer types. The recent food and drug administration approval of PD-1 inhibitors for mismatch repair (MMR)-deficient tumors has extended use of these treatments to all cancer types, and programmed death ligand 1 (PD-L1) positivity in tumor tissue has also been shown to predict susceptibility to immunotherapy. Despite these advances, the response to immunotherapy in endometrial cancer remains poorly understood. Here, we describe the case of a patient with MMR-proficient, PD-L1-negative stage IV endometrial cancer who exhibited a strong clinical response to combination PD-1 and CTLA-4 inhibition. She showed deep and durable ongoing partial response to nivolumab and ipilimumab that has persisted after 12 months. This case indicates the potential existence of an endometrial cancer subtype that is sensitive to immune checkpoint blockade based on mechanisms other than those driven by MMR deficiency or PD-L1 positivity. Improved understanding of immunotherapy in advanced endometrial cancer is clearly needed and offers the potential to significantly enhance patient outcomes.
Insights
This case study highlights a patient with advanced endometrial cancer who responded well to immune checkpoint inhibitors, even without typical biomarkers like MMR deficiency or PD-L1 positivity. Further research is needed to understand immunotherapy responses in this cancer type.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Immune checkpoint inhibitors (ICIs) like PD-1 and CTLA-4 blockers are effective cancer treatments.
- Biomarkers such as mismatch repair (MMR) deficiency and PD-L1 positivity predict ICI response in various cancers.
- The efficacy of immunotherapy in endometrial cancer is not fully understood.
Observation:
- A patient with stage IV endometrial cancer, who was MMR-proficient and PD-L1-negative, received combination PD-1 and CTLA-4 inhibition (nivolumab and ipilimumab).
- The patient experienced a significant and durable partial response lasting over 12 months.
Findings:
- This case suggests that some endometrial cancers may respond to ICIs through mechanisms independent of MMR deficiency or PD-L1 expression.
- The patient's response indicates a potential novel subtype of endometrial cancer sensitive to immune checkpoint blockade.
Implications:
- This finding broadens the potential application of immunotherapy in endometrial cancer.
- Further investigation into immunotherapy response mechanisms in advanced endometrial cancer is crucial for improving patient outcomes.
- Identifying new predictive biomarkers for immunotherapy in endometrial cancer is warranted.
More Related Videos
10:28Imaging Mismatch Repair and Cellular Responses to DNA Damage in Bacillus subtilis
Published on: February 8, 2010
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
Mismatch Repair
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Overview of DNA Repair
Chemically...
Neuromuscular Junction And Blockade
Inflammatory Response II: Inflammatory Exudate and Tissue Repair
The typical wound exudate is odorless, transparent, straw-colored, thin, and watery. Exudate, however, can differ depending on the state of wound healing. Likewise, the...
Brick Durability, Strength, and Appearance